jasthace
New Member
Re: Test for women
KY gel always works well
KY gel always works well
MESO-Rx
Anabolic Steroids
Female Sexual Dysfunction - Testosterone
- Thread starter Michael Scally MD
- Start date
porky little keg
New Member
Re: Test for women
all test aside...... just get a running start, she'll be fine...... just don't miss.
all test aside...... just get a running start, she'll be fine...... just don't miss.
Re: Test for women
All kidding aside, Tarzan, I would think 10 mg per week would do wonders, though it might take a while to kick in. If, as Michael suggests, you can get the bonafide LibiGel® cream (especially prescribed by a doctor) that's even better. You don't need lube, you need heightened libido and, for men or women, that's mostly testosterone in one form or another.
I don't think a slightly enlarged clit is such a bad thing: Much easier to find in the dark!
Solo
All kidding aside, Tarzan, I would think 10 mg per week would do wonders, though it might take a while to kick in. If, as Michael suggests, you can get the bonafide LibiGel® cream (especially prescribed by a doctor) that's even better. You don't need lube, you need heightened libido and, for men or women, that's mostly testosterone in one form or another.
I don't think a slightly enlarged clit is such a bad thing: Much easier to find in the dark!
Solo
jasthace
New Member
Re: Test for women
i would like to play with a slightly enlarged clit, it sounds kind of cute
I don't think a slightly enlarged clit is such a bad thing: Much easier to find in the dark!
Solo
i would like to play with a slightly enlarged clit, it sounds kind of cute
TZTARZAN2000
New Member
Re: Test for women
Solo, thank-you! Jasthace, KY sucks! they do have this stuffcalled liquid silk that iswaterbased and amazing. i dont mind the lube, especially after a marathon. its just the day or two after she has difficulty and it bothers her more then me. i totally understand. depending on what im doing i can keep it hard for a marathon too and then the next day or whatever i need a popsicle stick and duct tape. not really but you know what i mean. i feel like crap. thank the medical profession for cialias! so mentally we are in the same boat. i will give her a couple i/u's of prop to get it started and maybe 1 or 2 of cyp 2x a week. sound ok?
thanks again!
Solo, thank-you! Jasthace, KY sucks! they do have this stuffcalled liquid silk that iswaterbased and amazing. i dont mind the lube, especially after a marathon. its just the day or two after she has difficulty and it bothers her more then me. i totally understand. depending on what im doing i can keep it hard for a marathon too and then the next day or whatever i need a popsicle stick and duct tape. not really but you know what i mean. i feel like crap. thank the medical profession for cialias! so mentally we are in the same boat. i will give her a couple i/u's of prop to get it started and maybe 1 or 2 of cyp 2x a week. sound ok?
thanks again!
BPAX says it expects to submit the LibiGel NDA by the end of 2012.
BioSante Pharmaceuticals Completes Enrollment in LibiGel® Phase III Safety Study
http://finance.yahoo.com/news/BioSante-Pharmaceuticals-bw-2283110737.html?x=0&.v=1
BioSante Pharmaceuticals Completes Enrollment in LibiGel® Phase III Safety Study
http://finance.yahoo.com/news/BioSante-Pharmaceuticals-bw-2283110737.html?x=0&.v=1
Re: Flibanserin & Sexual Desire
No doubt true in some cases but not generally. From my 45 years of studying the issue in depth and from many points of view, the cause is more often than not one of psychological control issues.
That is ludicrous. Would be interesting to look into her personality. Puritianism lives on in America. [}
]
No doubt true in some cases but not generally. From my 45 years of studying the issue in depth and from many points of view, the cause is more often than not one of psychological control issues.
That is ludicrous. Would be interesting to look into her personality. Puritianism lives on in America. [}
]I am currently taking this (testosterone - as well as DHEA, progesterone, melatonin, estradiol?) as a supplement from the test results I received a couple of weeks ago. Perhaps you can assist me in another opinion as to what they all mean:
Saliva tests:
Estradiol 3.9H pg/ml
Progesterone 37L
Ratio 9L
Testosterone 25
DHEAs 14.1
Cortisol 6.6 (morning) 3.5 (afternoon and evening) 1.0 (night)
Blood work:
TSH, 3rd Gen 2.43 mIU/L
T4 Total 7.3 mcg/dl
T4 Free 1.2 ng/dl
T3 Free 2.2 pg/ml
T3 Reverse 25 ng/dl
Read more from the MESO-Rx Steroid Forum at: https://thinksteroids.com/community/threads/134304147
Saliva tests:
Estradiol 3.9H pg/ml
Progesterone 37L
Ratio 9L
Testosterone 25
DHEAs 14.1
Cortisol 6.6 (morning) 3.5 (afternoon and evening) 1.0 (night)
Blood work:
TSH, 3rd Gen 2.43 mIU/L
T4 Total 7.3 mcg/dl
T4 Free 1.2 ng/dl
T3 Free 2.2 pg/ml
T3 Reverse 25 ng/dl
Read more from the MESO-Rx Steroid Forum at: https://thinksteroids.com/community/threads/134304147
BioSante Female Sex Drug Spurs Deal-Making Talks, CEO Says
BioSante Female Sex Drug Spurs Deal-Making Talks, CEO Says - Bloomberg
BioSante Female Sex Drug Spurs Deal-Making Talks, CEO Says - Bloomberg
Braunstein GD, Reitz RE, Buch A, Schnell D, Caulfield MP. Testosterone Reference Ranges in Normally Cycling Healthy Premenopausal Women. J Sex Med. Testosterone Reference Ranges in Normally Cycling Healthy Premenopausal Women - Braunstein - 2011 - The Journal of Sexual Medicine - Wiley Online Library
Introduction. At present, there are no well-accepted reference ranges for serum testosterone concentrations in women.
Aim. The aim of this study was to determine the reference ranges for serum testosterone and sex hormone-binding globulin (SHBG) in premenopausal women with normal menstrual cycles.
Methods. We measured serum total, free, and bioavailable testosterone and SHBG concentrations in 161 healthy, normally cycling women (18-49 years). Morning blood samples were collected during follicular, mid-cycle, and luteal phases of the menstrual cycle and analyzed using validated methods. Mean, median, and weighted average hormone levels across menstrual cycle phases as well as percentiles for a typical 30-year-old woman were determined.
Main Outcome Measures. Age-related serum levels of total, free, and bioavailable testosterone and SHBG levels in normally cycling premenopausal women.
Results. Serum testosterone concentrations exhibited an age-related decline, whereas SHBG remained relatively stable across studied age ranges. Reference ranges for total, free, and bioavailable testosterone and SHBG were established using 5th and 95th percentiles. The estimated 5th and 95th percentiles for a 30-year-old woman were: testosterone, 15-46 ng/dL (520-1595 pmol/L); free testosterone, 1.2-6.4 pg/mL (4.16-22.2 pmol/L); calculated free testosterone, 1.3-5.6 pg/mL (4.5-19.4 pmol/L); bioavailable testosterone, 1.12-7.62 ng/dL (38.8-264.21 pmol/L); and SHBG 18-86 nmol/L. The variations of hormones and SHBG across menstrual cycle were consistent with previous literature.
Conclusions. Reference ranges for free, total, and bioavailable testosterone and SHBG were established in premenopausal women using validated immunoassays and an adequate number of subjects consistent with recommendations by the National Committee for Clinical Laboratory Standards. The increase in testosterone in the mid-cycle period is relatively small compared with the overall variability, so these reference ranges can be applied irrespective of the day in the menstrual cycle the sample has been taken.
Introduction. At present, there are no well-accepted reference ranges for serum testosterone concentrations in women.
Aim. The aim of this study was to determine the reference ranges for serum testosterone and sex hormone-binding globulin (SHBG) in premenopausal women with normal menstrual cycles.
Methods. We measured serum total, free, and bioavailable testosterone and SHBG concentrations in 161 healthy, normally cycling women (18-49 years). Morning blood samples were collected during follicular, mid-cycle, and luteal phases of the menstrual cycle and analyzed using validated methods. Mean, median, and weighted average hormone levels across menstrual cycle phases as well as percentiles for a typical 30-year-old woman were determined.
Main Outcome Measures. Age-related serum levels of total, free, and bioavailable testosterone and SHBG levels in normally cycling premenopausal women.
Results. Serum testosterone concentrations exhibited an age-related decline, whereas SHBG remained relatively stable across studied age ranges. Reference ranges for total, free, and bioavailable testosterone and SHBG were established using 5th and 95th percentiles. The estimated 5th and 95th percentiles for a 30-year-old woman were: testosterone, 15-46 ng/dL (520-1595 pmol/L); free testosterone, 1.2-6.4 pg/mL (4.16-22.2 pmol/L); calculated free testosterone, 1.3-5.6 pg/mL (4.5-19.4 pmol/L); bioavailable testosterone, 1.12-7.62 ng/dL (38.8-264.21 pmol/L); and SHBG 18-86 nmol/L. The variations of hormones and SHBG across menstrual cycle were consistent with previous literature.
Conclusions. Reference ranges for free, total, and bioavailable testosterone and SHBG were established in premenopausal women using validated immunoassays and an adequate number of subjects consistent with recommendations by the National Committee for Clinical Laboratory Standards. The increase in testosterone in the mid-cycle period is relatively small compared with the overall variability, so these reference ranges can be applied irrespective of the day in the menstrual cycle the sample has been taken.
Managing Low Sexual Desire In Women
Low sexual desire is a common problem amongst women of all ages. When associated with distress, it is termed hypoactive sexual desire disorder (HSDD), which is estimated to affect approximately one in ten women. Unfortunately, women are often reluctant to report the symptom of low sexual desire, despite the fact that it is a prevalent and distressing condition for many women, associated with a range of negative effects on women’s health. This article aims to give a practical overview on the identification and management of this disorder by reviewing the most recent and relevant literature on the subject.
Summary:
Female Sexual Function
• Female sexual dysfunction is commonly classified into distinct disorders of desire, arousal, orgasm or pain. In clinical practice, these disorders frequently overlap.
• Hypoactive sexual desire disorder (HSDD) is defined as low sexual desire that causes distress or relationship difficulties.
Epidemiology
• HSDD affects 6–16% of women in Europe and menopausal status has a significant impact on its prevalence.
• HSDD has important effects on women’s wellbeing and is associated with low self-esteem, depression and relationship dissatisfaction.
• Etiology
• Low sexual desire can result from a variety of physiological, psychological and sociocultural factors.
• Estrogens and androgens play a crucial role and interact with various neurotransmitters to modulate sexual desire.
Assessment
• A thorough history will uncover many causes for sexual dysfunction that may be treated with the specialist psychosexual environment such as medication side-effects or medical comorbidities.
Management of HSDD
• A greater understanding of the female sexual response has helped identify many potential biological and psychosocial targets for therapeutic intervention.
• Management of HSDD requires an individual approach incorporating pharmacological and psychosocial interventions.
Hormonal Management
• Menopause is a time particularly associated with sexual dysfunction and estrogen and testosterone replacement can be valuable in improving sexual function.
• The transdermal testosterone patch is licensed in Europe for the treatment of HSDD in surgically menopausal women on concomitant HRT.
• No pharmacologic therapy is currently approved for the treatment of HSDD in premenopausal or naturally postmenopausal women and further research is urgently needed in these populations.
• At present there is no evidence that dihydroepiandrosterone supplements should be used for HSDD as its safety and efficacy are currently unclear.
Other Treatments
• Despite evidence supporting the use of flibanserin for HSDD, its development has been withdrawn owing to safety concerns.
• Bupropion is associated with an improvement in sexual desire and may be particularly useful in selective serotonin reuptake inhibitor-induced low desire.
• In the future, improved understanding of the neurochemical pathways of sexual desire may help aid development of more selective agents.
Maclaran K, Panay N. Managing low sexual desire in women. Womens Health (Lond Engl) 2011;7(5):571-83. http://www.futuremedicine.com/doi/pdf/10.2217/whe.11.54 (An Error Occurred Setting Your User Cookie)
Low sexual desire is a prevalent symptom, but not one frequently volunteered by women. When accompanied by distress, loss of libido is known as hypoactive sexual desire disorder, which can have a significant impact on a woman's wellbeing. The etiology of hypoactive sexual desire disorder is multifactorial and its management requires a combination of psychosocial and pharmacological interventions. This article outlines the assessment of patients presenting with the symptom of low sexual desire and discusses the evidence for pharmacological management.
Low sexual desire is a common problem amongst women of all ages. When associated with distress, it is termed hypoactive sexual desire disorder (HSDD), which is estimated to affect approximately one in ten women. Unfortunately, women are often reluctant to report the symptom of low sexual desire, despite the fact that it is a prevalent and distressing condition for many women, associated with a range of negative effects on women’s health. This article aims to give a practical overview on the identification and management of this disorder by reviewing the most recent and relevant literature on the subject.
Summary:
Female Sexual Function
• Female sexual dysfunction is commonly classified into distinct disorders of desire, arousal, orgasm or pain. In clinical practice, these disorders frequently overlap.
• Hypoactive sexual desire disorder (HSDD) is defined as low sexual desire that causes distress or relationship difficulties.
Epidemiology
• HSDD affects 6–16% of women in Europe and menopausal status has a significant impact on its prevalence.
• HSDD has important effects on women’s wellbeing and is associated with low self-esteem, depression and relationship dissatisfaction.
• Etiology
• Low sexual desire can result from a variety of physiological, psychological and sociocultural factors.
• Estrogens and androgens play a crucial role and interact with various neurotransmitters to modulate sexual desire.
Assessment
• A thorough history will uncover many causes for sexual dysfunction that may be treated with the specialist psychosexual environment such as medication side-effects or medical comorbidities.
Management of HSDD
• A greater understanding of the female sexual response has helped identify many potential biological and psychosocial targets for therapeutic intervention.
• Management of HSDD requires an individual approach incorporating pharmacological and psychosocial interventions.
Hormonal Management
• Menopause is a time particularly associated with sexual dysfunction and estrogen and testosterone replacement can be valuable in improving sexual function.
• The transdermal testosterone patch is licensed in Europe for the treatment of HSDD in surgically menopausal women on concomitant HRT.
• No pharmacologic therapy is currently approved for the treatment of HSDD in premenopausal or naturally postmenopausal women and further research is urgently needed in these populations.
• At present there is no evidence that dihydroepiandrosterone supplements should be used for HSDD as its safety and efficacy are currently unclear.
Other Treatments
• Despite evidence supporting the use of flibanserin for HSDD, its development has been withdrawn owing to safety concerns.
• Bupropion is associated with an improvement in sexual desire and may be particularly useful in selective serotonin reuptake inhibitor-induced low desire.
• In the future, improved understanding of the neurochemical pathways of sexual desire may help aid development of more selective agents.
Maclaran K, Panay N. Managing low sexual desire in women. Womens Health (Lond Engl) 2011;7(5):571-83. http://www.futuremedicine.com/doi/pdf/10.2217/whe.11.54 (An Error Occurred Setting Your User Cookie)
Low sexual desire is a prevalent symptom, but not one frequently volunteered by women. When accompanied by distress, loss of libido is known as hypoactive sexual desire disorder, which can have a significant impact on a woman's wellbeing. The etiology of hypoactive sexual desire disorder is multifactorial and its management requires a combination of psychosocial and pharmacological interventions. This article outlines the assessment of patients presenting with the symptom of low sexual desire and discusses the evidence for pharmacological management.
Goldfischer ER, Breaux J, Katz M, et al. Continued Efficacy and Safety of Flibanserin in Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD): Results from a Randomized Withdrawal Trial. J Sex Med. Continued Efficacy and Safety of Flibanserin in Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD): Results from a Randomized Withdrawal Trial - Goldfischer - 2011 - The Journal of Sexual Medicine - Wiley Online Library
Introduction. Flibanserin is a 5-HT(1A) agonist/5-HT(2A) antagonist that has been shown to increase sexual desire and reduce distress in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD).
Aim. To assess the efficacy and safety of flibanserin over 24 weeks of double-blind treatment vs. placebo in premenopausal women with HSDD who showed a predefined response after 24 weeks of open-label treatment with flibanserin.
Methods. Women (N = 738) were treated with open-label, flexible-dose flibanserin (50 mg or 100 mg/day) for 24 weeks. At week 24, women who showed a predefined response, measured using an eDiary, were randomized to 24 weeks of continued flibanserin therapy at optimized dosage (N = 163) or placebo (N = 170). The criteria for entering the double-blind phase were an increase from baseline to weeks 21-24 of >/=2 satisfying sexual events (SSE) and/or >/=4 "desire days." A "desire day" was one in which a woman reported more than "no" desire.
Main Outcome Measures. Coprimary endpoints were change from randomization to study end in SSE and desire score. Secondary measures included change in Female Sexual Function Index (FSFI) total and desire domain scores and Female Sexual Distress Scale-Revised (FSDS-R) total and Item 13 scores.
Results. During the open-label period, mean SSE and desire score approximately doubled, and FSFI, FSDS-R total, and Item 13 scores improved. At the end of the double-blind period, flibanserin was superior to placebo in change from randomization in SSE, desire score, FSFI desire domain and total scores, and FSDS-R total and Item 13 scores (P < 0.05, for all). Flibanserin was well tolerated, and withdrawal reactions were not observed.
Conclusions. At the end of the 24-week randomized withdrawal phase of a 48-week trial in premenopausal women with HSDD, flibanserin was superior to placebo on measures of SSE, sexual desire, overall sexual function, and sexual distress. Flibanserin was well tolerated, and no withdrawal reactions were observed following discontinuation.
Introduction. Flibanserin is a 5-HT(1A) agonist/5-HT(2A) antagonist that has been shown to increase sexual desire and reduce distress in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD).
Aim. To assess the efficacy and safety of flibanserin over 24 weeks of double-blind treatment vs. placebo in premenopausal women with HSDD who showed a predefined response after 24 weeks of open-label treatment with flibanserin.
Methods. Women (N = 738) were treated with open-label, flexible-dose flibanserin (50 mg or 100 mg/day) for 24 weeks. At week 24, women who showed a predefined response, measured using an eDiary, were randomized to 24 weeks of continued flibanserin therapy at optimized dosage (N = 163) or placebo (N = 170). The criteria for entering the double-blind phase were an increase from baseline to weeks 21-24 of >/=2 satisfying sexual events (SSE) and/or >/=4 "desire days." A "desire day" was one in which a woman reported more than "no" desire.
Main Outcome Measures. Coprimary endpoints were change from randomization to study end in SSE and desire score. Secondary measures included change in Female Sexual Function Index (FSFI) total and desire domain scores and Female Sexual Distress Scale-Revised (FSDS-R) total and Item 13 scores.
Results. During the open-label period, mean SSE and desire score approximately doubled, and FSFI, FSDS-R total, and Item 13 scores improved. At the end of the double-blind period, flibanserin was superior to placebo in change from randomization in SSE, desire score, FSFI desire domain and total scores, and FSDS-R total and Item 13 scores (P < 0.05, for all). Flibanserin was well tolerated, and withdrawal reactions were not observed.
Conclusions. At the end of the 24-week randomized withdrawal phase of a 48-week trial in premenopausal women with HSDD, flibanserin was superior to placebo on measures of SSE, sexual desire, overall sexual function, and sexual distress. Flibanserin was well tolerated, and no withdrawal reactions were observed following discontinuation.
'Viagra for Women’ Gets Push for F.D.A. Approval
http://www.nytimes.com/2015/06/01/business/groups-press-fda-to-approve-womens-viagra.html
http://www.nytimes.com/2015/06/01/business/groups-press-fda-to-approve-womens-viagra.html
Similar threads
